Q-omics provides the consensus-scored RN7SL692P profile across patient tissues and cancer cell-line models. RN7SL692P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RN7SL692P is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, RN7SL692P RNA expression shows 6,392 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, THCA, and STAD as cancer lineages where RN7SL692P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL692P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL692P survival associations across molecular data types. RN7SL692P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL692P RNA expression–survival associations across cancer types. High RN7SL692P expression shows unfavorable associations in KIRC, UVM, LUSC, BLCA and OV, but favorable associations in STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RN7SL692P RNA expression.
This table summarizes RN7SL692P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL692P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL692P shows lower tumor expression in THCA. The THCA box plot shows higher RN7SL692P RNA expression in normal versus tumor tissue (log2 FC = −0.033, t-test p = .018).
This table shows molecular features associated with RN7SL692P in patient tissues and cancer cell lines. In patient samples, RN7SL692P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
